Guillain-Barre syndrome is a serious disorder that occurs when the body's defense (immune) system mistakenly attacks part of the nervous system. This leads to nerve inflammation that causes muscle weakness .
Landry-Guillain-Barre syndrome; GBS; Acute idiopathic polyneuritis; Infectious polyneuritis; Acute inflammatory polyneuropathy
Causes, incidence, and risk factors:
Guillain-Barre syndrome is an autoimmune disorder (the body's immune system attacks itself). Exactly what triggers Guillain-Barre syndrome is unknown. The syndrome may occur at any age, but is most common in people of both sexes between ages 30 and 50.
It often follows a minor infection, usually a lung infection or gastrointestinal infection. Usually, signs of the original infection have disappeared before the symptoms of Guillain-Barre begin.
Guillain-Barre syndrome causes inflammation that damages parts of nerves. This nerve damage causes tingling, muscle weakness , and paralysis . The inflammation usually affects the nerve's covering (myelin sheath). Such damage is called demyelination . Demyelination slows nerve signaling. Damage to other parts of the nerve can cause the nerve to stop working.
Guillain-Barre syndrome may occur along with viral infections such as:
It may also occur with other medical conditions such as systemic lupus erythematosus or Hodgkin's disease .
Some people may get Guillain-Barre syndrome after a bacterial infection or certain vaccinations (such as rabies and swine flu). A similar syndrome may occur after surgery, or when critically ill.
Symptoms of Guillain-Barre can get worse very quickly. It may take only a few hours to reach the most severe symptoms, but weakness increasing over several days is also common.
Muscle weakness or the loss of muscle function (paralysis) affects both sides of the body. In most cases, the muscle weakness starts in the legs and then spreads to the arms. This is called ascending paralysis.
Patients may notice tingling, foot or hand pain, and clumsiness. If the inflammation affects the nerves to the diaphragm, and there is weakness in those muscles, the person may need breathing assistance.
Typical symptoms include:
- Loss of reflexes in the arms and legs
- Muscle weakness or loss of muscle function (paralysis)
- In mild cases, there may be no weakness or paralysis
- May begin in the arms and legs at the same time
- May get worse over 24 to 72 hours
- May occur in the nerves of the head only
- May start in the arms and move downward
- May start in the feet and legs and move up to the arms and head
- Numbness , decreased sensation
- Sensation changes
- Tenderness or muscle pain (may be a cramp-like pain)
- Uncoordinated movement
Additional symptoms may include:
- Blurred vision
- Clumsiness and falling
- Difficulty moving face muscles
- Muscle contractions
- Palpitations (sensation of feeling heartbeat)
Emergency symptoms (seek immediate medical help):
Signs and tests:
A history of increasing muscle weakness and paralysis may be a sign of Guillain-Barre syndrome, especially if there was a recent illness.
A medical exam may show muscle weakness and problems with involuntary (autonomic) body functions such as blood pressure and heart rate. The examination may also show that reflexes, such as the "knee jerk," are decreased or missing.
There may be signs of decreased breathing (caused by paralysis of the breathing muscles).
The following tests may be ordered:
- Cerebrospinal fluid sample ("spinal tap") may have increased levels of protein without an increase in white blood cells.
- ECG may show heart problems in some cases.
- EMG tests the electrical activity in muscles. It may show that nerves do not react properly to stimulation.
- Nerve conduction velocity test shows that electrical activity along the nerves is slowed or blocked.
There is no cure for Guillain-Barre syndrome. However, many treatments are available to help reduce symptoms, treat complications, and speed up recovery.
When symptoms are severe, the patient will need to go to the hospital for breathing help, treatment, and physical therapy.
A method called plasmapheresis is used to remove proteins, called antibodies , from the blood. The process involves taking blood from the body, usually from the arm, pumping it into a machine that removes the antibodies, then sending it back into the body.
High-dose immunoglobulin therapy (IVIg) is another treatment used to reduce the severity and length of Guillain-Barre symptoms. In this case, the immunoglobulins are added to the blood in large quantity, blocking the antibodies that cause inflammation.
Other treatments are directed at preventing complications.
- Blood thinners may be used to prevent blood clots.
- If the diaphragm is week, breathing support or even a breathing tube and ventilator may be needed.
- Pain is treated aggressively with anti-inflammatory medicines and narcotics, if needed.
- Proper body positioning or a feeding tube may be used to prevent choking during feeding if the muscles for swallowing are weak.
Guillain-Barre Syndrome Foundation International - www.gbsfi.com
Recovery can take weeks or years. Most people survive and recover completely. According to the National Institute of Neurological Disorders and Stroke, about 30% of patients still have some weakness after 3 years. Mild weakness may persist for some people.
A patient's outcome is most likely to be very good when the symptoms go away within 3 weeks after they first started.
- Breathing difficulty (respiratory failure)
- Contractures of joints or other deformity
- Deep vein thrombosis (blood clots that form when someone is inactive or confined to bed)
- Increased risk of infections
- Low or unstable blood pressure
- Permanent loss of movement of an area
- Sucking food or fluids into the lungs (aspiration )
Calling your health care provider:
Seek immediate medical help if you have any of the following symptoms:
- Can't take a deep breath
- Decreased feeling (sensation)
- Difficulty breathing
- Difficulty swallowing
- Loss of movement
Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2009;(1):CD002063.
Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-740.
Sharar E. Current therapeutic options in severe Guillain-Barre syndrome. Clin Neuropharmacol. 2006;29(1):45-51.
Roos KL. Viral infections. In: Goetz CG, ed. Textbook of Clinical Neurology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2007:chap 41.